20S Immunoproteasome (human) (untagged)
Human 20S Immunoproteasome.
Experiments should be carried out at 20S immunoproteasome concentrations between 2-5nM. The 20S immunoproteasome is commonly associated with the 19S, PA28 α/β, or the PA28γ regulatory complexes. If choosing to omit PA28 during use, 20S must be chemically activated by addition of 0.035%SDS in final assay buffers.
|Formulation||Liquid. In 50mM HEPES pH 7.5, 100mM sodium chloride, 1mM TCEP.|
|Other Product Data||
Click here for a Typical Lot-specific Product Datasheet from the Original Manufacturer
|Declaration||Manufactured by South Bay Bio.|
|Shipping and Handling|
|Short Term Storage||-80°C|
|Long Term Storage||-80°C|
|Handling Advice||Aliquot to avoid freeze/thaw cycles.|
|Use/Stability||Stable for at least 1 year after receipt when stored at -80°C.|
|Product Specification Sheet|
The 20S immunoproteasome is structurally similar to constitutive 26S proteasome. The 20S core of immunoproteasome contains two outer rings composed of α-subunits, and two internal 7-subunit containing rings each possessing 3 specific subunits responsible for proteasome catalytic activity. In immunoproteasomes these subunits (ß1, ß2, ß5) are replaced by three inducible subunits: PSMB9, PSMB10 and PSMB8, (ß1i, ß2i, ß5i). These stress-induced subunits allow for the production of MHC-1 associating peptides, which are displayed as antigens on the cell surface. These displayed peptides can then be recognized by immune surveillance CD8 T cells. 20S immunoproteasome is recognized as a strong drug target for autoimmune disease and cancer.